Inovio Pharmaceuticals Inc.

Inovio Pharmaceuticals Inc. is taking immunotherapy to the next level in the fight against cancer and infectious diseases. They are the only immunotherapy company that has reported generating T cells in vivo in high quantity that are fully functional and whose killing capacity correlates with relevant clinical outcomes with a favorable safety profile. With an expanding portfolio of immune therapies, the company is advancing a growing preclinical and clinical stage product pipeline. Partners and collaborators include MedImmune, Roche, The Wistar Institute, University of Pennsylvania, DARPA, GeneOne Life Science, Plumbline Life Sciences, Drexel University, NIH, HIV Vaccines Trial Network, National Cancer Institute, U.S. Military HIV Research Program, and University of Manitoba.

Expert Comments:

Inovio's Zika vaccine has demonstrated robust antigen-specific antibody responses in a Phase 1 study with 40 volunteers.
read more >
Ram Selvaraju, H.C. Wainwright & Co. (12/22/16)
"Inovio Pharmaceuticals Inc. announced that its DNA-based Zika vaccine (GLS-5700) had generated robust antigen-specific antibody responses in healthy adult volunteers in a multi-center first-in-human Phase 1 trial. Both the low-dose and the high-dose vaccine groups demonstrated positive responses after one or two vaccinations. . .management expects to complete the second Zika vaccine Phase 1 trial in 160 subjects in Puerto Rico by the end of 2016 and report data in 2017. . .Inovio and The Wistar Institute have received an $8.8M grant from the Bill & Melinda Gates Foundation to develop a DNA-based monoclonal antibody."

Douglas House, Seeking Alpha (12/21/16)
"Inovio Pharmaceuticals Inc. perked up on increased volume in response to its announcement of positive results from a Phase 1 trial assessing its DNA-based Zika vaccine GLS-5700. . .Zika-naive subjects in the low-dose and high-dose groups showed Zika antigen-specific antibody responses after one or two vaccinations. . .a second Phase I involving 160 subjects in Puerto Rico should be completed shortly. The company intends to meet with regulators to discuss the data from the two studies and clarify a regulatory path leading to a marketing application."

Betsy McKay and Peter Loftus, The Wall Street Journal (12/15/16)
"The Zika epidemic is accelerating work on this other experimental DNA vaccines, which could turn out to be America's best defense against infectious-disease outbreaks that now spread around the world with alarming speed, fueled by rising populations and global travel. These vaccines, made with synthetic DNA, can be developed and manufactured quickly. . .Inovio Pharmaceuticals Inc. is in a race to market its vaccine and accompanying "electroporation device," a tool the size of an electric toothbrush that uses a jolt of electricity to help usher the firm's DNA vaccine into human cells."

Nick Hodge's Early Advantage (11/10/16)
"The Trump Bump has seen Inovio Pharmaceuticals Inc. rise nearly 28% in the past five days. It reported a $20.8 million Q3 loss this week, beating on revenues of $12.5 million. . .this play isn't about quarterly earnings. It's about the multiple drugs it has in development for serious diseases with major pharmaceutical partners. . .we're up 12% on Inovio and it remains a buy."

Ram Selvaraju, H.C. Wainwright & Co. (11/10/16)
"Inovio Pharmaceuticals Inc. total revenue was $12.5M, and net loss was $20.8M during the quarter, or ($0.28) per share. . .management expects to complete the FDA requirement regarding additional data on the shelf-life of the disposal part of the Cellectra® 5PSP delivery device in 1Q17. . .management has indicated that this pivotal study for VGX-3100 is scheduled to enroll approximately 400 subjects, up from 350 subjects as previously suggested. . .the company plans to have three drug candidates ready for registration in 2020. . .Inovio had $119.7M in cash and investments, which should fund operations into 2018."

Charles Duncan, Piper Jaffray & Co. (11/9/16)
"Inovio Pharmaceuticals Inc.'s lead program of ‘3100 in cervical dysplasia unfortunately remains on clinical hold. . .we believe the known concerns re: shelf-life of the CELLECTRA device can be efficiently addressed with 6-week non-clinical testing that Inovio has already initiated. . .while visibility is constrained in the near-term, following today's updates we remain buyers of INO shares in anticipation of a smooth turn-around and 1H17 trial start for ‘3100, and upside from its Phase I Zika (4Q16) and Ebola (1H17) results."

Inovio Pharmaceuticals Inc. (INO:NASDAQ) has expanded the Phase 1 trial of its Ebola vaccine to include an additional 125 healthy subjects. This, according to Maxim Group analyst Jason Kolbert, will help the company determine an "optimal" strategy for intradermal (skin) vaccination.
read more >

More Expert Comments

Experts Following This Company

Larry Biegelsen – Wells Fargo Securities
Jim Birchenough – BMO Capital Markets
Charles Duncan, Managing Director, Senior Biotechnology Analyst – Piper Jaffray & Co.
Nick Hodge, Founder and president of the Outsider Club – Outsider Club
Jason Kolbert, Senior Analyst – Maxim Group
Jason McCarthy, Analyst – Maxim Group
Ram Selvaraju, Managing Director; Head of Healthcare Equity Research – Rodman & Renshaw

The information provided above is from analysts, newsletters, the company and other contributors.

Inovio Pharmaceuticals Inc. is a sponsor of Streetwise Reports. The company's sponsorship fees pay for Streetwise Reports to create and update this "Investor Summary Page," to which links are placed on Streetwise Reports' websites and newsletters. Streetwise Reports does not accept stock for the payment of fees. See disclaimer for more details.

The company description, investing highlights and catalyst calendar on this page were prepared by the company. The Expert Comments and Experts Following This Company sections of this page are compiled by Streetwise Reports. There may be other information about the company that is not placed on this page. Streetwise Reports does not guarantee the accuracy or thoroughness of the information contained on this page.

Streetwise Reports does not provide investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security.Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.

Readers should conduct their own research for all information publicly available concerning the company.